MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer

被引：0
|
作者：
Kaur, J. [1 ]
Martinez-Martin, S. [2 ]
Foradada, L. [2 ]
Lopez-Estevez, S. [2 ]
Serrano, E. [1 ]
Martin-Fernandez, G. [1 ]
Thabussot, H. [3 ]
Cano, V. Castillo [3 ]
Casacuberta-Serra, S. [4 ]
Zacarias-Fluck, M. F. [1 ]
Grueso, J. [1 ]
Beaulieu, M. E. [5 ]
Whitfield, J. R.
Soucek, L. [1 ,5 ,6 ,7 ]
机构：
[1] Vall dHebron Inst Oncol, Models Canc Therapies Grp, Barcelona, Spain
[2] Peptomyc SL, Biomarkers, Barcelona, Spain
[3] Peptomyc SL, Prot Prod Platform, Barcelona, Spain
[4] Peptomyc SL, Immuno Oncol, Barcelona, Spain
[5] Peptomyc SL, Peptomyc, Barcelona, Spain
[6] Inst Catalana Recerca & Estudis Avancats, Icrea, Barcelona, Spain
[7] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [41] p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer
    Vinciguerra, Gian Luca Rampioni
    Dall'Acqua, Alessandra
    Segatto, Ilenia
    Mattevi, Maria Chiara
    Russo, Francesca
    Favero, Andrea
    Cirombella, Roberto
    Mungo, Giorgia
    Viotto, Davide
    Karimbayli, Javad
    Pesce, Margherita
    Vecchione, Andrea
    Belletti, Barbara
    Baldassarre, Gustavo
    CELL DEATH & DISEASE, 2021, 12 (10)
  • [42] DECIPHERING THE ROLE OF PARP-1 AS A THERAPEUTIC TARGET IN KRAS-MUTATED INTRAHEPATIC CHOLANGIOCARCINOMA
    Mahn, Friederike L.
    Castven, Darko
    Pereira, Sharon P.
    Hartmann, Monika
    Fahrer, Jorg
    Oliveira, Douglas V.
    Andersen, Jesper B.
    Matter, Matthias
    Roessler, Stephanie
    Kaina, Bernd
    Galle, Peter R.
    Marquardt, Jens U.
    HEPATOLOGY, 2019, 70 : 1143A - 1143A
  • [43] Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancer
    Kwon, Young-Ju
    Kim, Dong Young
    Kim, Uk-Il
    Kim, Song Hyun
    Kim, Ye-hyun
    Kim, Kyungjin
    Kim, Jae-Sung
    BIOCHEMICAL PHARMACOLOGY, 2025, 235
  • [44] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [45] Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
    Tsubaki, Masanobu
    Takeda, Tomoya
    Matsuda, Takuya
    Kishimoto, Kana
    Takefuji, Honoka
    Taniwaki, Yuzuki
    Ueda, Misa
    Hoshida, Tadafumi
    Tanabe, Kazufumi
    Nishida, Shozo
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [46] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [47] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
  • [48] Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
    Masanobu Tsubaki
    Tomoya Takeda
    Takuya Matsuda
    Kana Kishimoto
    Honoka Takefuji
    Yuzuki Taniwaki
    Misa Ueda
    Tadafumi Hoshida
    Kazufumi Tanabe
    Shozo Nishida
    Cancer Cell International, 23
  • [49] Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
    Watanabe, Fumiaki
    Suzuki, Koichi
    Tamaki, Sawako
    Abe, Iku
    Endo, Yuhei
    Takayama, Yuji
    Ishikawa, Hideki
    Kakizawa, Nao
    Saito, Masaaki
    Futsuhara, Kazushige
    Noda, Hiroshi
    Konishi, Fumio
    Rikiyama, Toshiki
    PLOS ONE, 2019, 14 (12):
  • [50] Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
    O'Sullivan, Eabha
    Keogh, Anna
    Henderson, Brian
    Finn, Stephen P.
    Gray, Steven G.
    Gately, Kathy
    CANCERS, 2023, 15 (06)
12345